)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SpringWorks Therapeutics
SpringWorks Therapeutics (SWTX) investor relations material
SpringWorks Therapeutics has been delisted
SpringWorks Therapeutics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary8 May, 2025
Executive summary
SpringWorks Therapeutics is a commercial-stage biopharma focused on rare diseases and oncology, with two FDA-approved products: OGSIVEO and GOMEKLI, and a pipeline of clinical and preclinical candidates.
OGSIVEO (nirogacestat) is approved for adult desmoid tumors; GOMEKLI (mirdametinib) is approved for NF1-associated plexiform neurofibromas in adults and children.
On April 27, 2025, SpringWorks entered into a merger agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $47.00 per share in cash, pending customary closing conditions.
Financial highlights
Net product revenue for Q1 2025 was $49.1 million, up 134% year-over-year from $21.0 million in Q1 2024, driven by OGSIVEO and GOMEKLI launches.
Net loss for Q1 2025 was $83.2 million, compared to $87.4 million in Q1 2024, a 5% improvement.
Cash, cash equivalents, and marketable securities totaled $382.7 million as of March 31, 2025, down from $461.9 million at year-end 2024.
Operating expenses increased to $129.6 million in Q1 2025 from $114.9 million in Q1 2024, mainly due to higher SG&A costs for commercialization.
Net cash used in operating activities was $68.8 million for Q1 2025, compared to $78.9 million in Q1 2024.
Outlook and guidance
Management expects current liquidity to fund operations for at least twelve months from the reporting date.
Profitability is anticipated in the first half of 2026, contingent on continued commercial success of OGSIVEO and GOMEKLI.
Pre-commercial preparations for OGSIVEO and GOMEKLI are underway in Europe, with regulatory decisions expected in 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SpringWorks Therapeutics
- First-in-class oncology therapies OGSIVEO and GOMEKLI fuel growth, global expansion, and pipeline momentum.SWTX
Corporate Presentation - OGSIVEO and mirdametinib drive growth as SpringWorks advances a robust, diversified oncology pipeline.SWTXCorporate Presentation
- Ogsiveo and mirtametinib launches drive growth, with strong data and expanding global reach.SWTX7th Annual Evercore ISI HealthCONx Healthcare Conference
- Rapid market adoption and pipeline progress signal major growth ahead.SWTXJefferies London Healthcare Conference 2024
- Ogsiveo surpasses forecasts, with strong U.S. growth, new formulations, and European launch ahead.SWTXGuggenheim’s Inaugural Healthcare Innovation Conference
- OGSIVEO revenue jumped 23% QoQ to $49.3M as net loss narrowed and pipeline advanced.SWTXQ3 2024
- Q2 revenue hit $59.7M, OGSIVEO led sales, net loss narrowed, mirdametinib NDA submitted.SWTXQ2 2024
- Ogsiveo and mirdametinib drive growth, with strong adoption, market confidence, and pipeline momentum.SWTXGoldman Sachs 45th Annual Global Healthcare Conference
- Strong product launches and pipeline progress support global growth and profitability by 2026.SWTX43rd Annual J.P. Morgan Healthcare Conference 2025
SpringWorks Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SpringWorks Therapeutics Inc. is a biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company leverages a precision medicine approach to develop therapies that target critical pathways in these diseases. SpringWorks' portfolio includes investigational therapies designed to modulate the activity of key proteins and signaling pathways involved in disease progression. The company collaborates with other pharmaceutical firms and research institutions to advance its clinical programs and bring innovative treatments to market. The company is headquartered in Stamford, Connecticut, and its shares are listed on the NASDAQ.